Private Placement

A massive co-investment targets 6,000 apartments in Atlanta and D.C. for upgrades, signaling institutional confidence and raising affordability questions.

The diversified company is pivoting to Web3, partnering to transform high-value memorabilia like sports cards and art into tradable digital assets.

Real estate icon Fredrik Eklund partners with co-ownership firm Pacaso. Is this the future of luxury property or just a new form of exclusivity?

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

With a new EV plant in Santa Teresa, GreenPower aims for market dominance while New Mexico pushes its ambitious clean energy and economic development goals.

A breakthrough liquid biopsy shows over 80% accuracy in finding feline lymphoma, offering a non-invasive screening tool for vets and hope for cat owners.

Safi Biotherapeutics and ARMI | BioFabUSA achieve a critical step toward mass-producing red blood cells, offering hope for patients and military readiness.

The biotech firm launches an early access program for its novel platform, starting with a tau assay that could revolutionize Alzheimer's research.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

A new national reimbursement code for NeurAxis's IB-Stim therapy is set to revolutionize access for chronic GI pain patients, validating the technology.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

With a potential winter drill program at its Tharsis REE project and high-grade results at Big Mack, the company is advancing two key Canadian assets.

With record growth and a fortified cash position, ElevateBio combines AI-driven discovery and industrial-scale manufacturing to power the gene therapy boom.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.

Westwater Resources heads to a key investor conference, carrying the weight of its Alabama graphite projects and the future of America's EV supply chain.

How a blend of private capital and pragmatic regulation is turning Singapore into a global hub for longevity research, pushing scientific and ethical boundaries.

Oculis is advancing a neuroprotective drug for optic neuropathies and a first-of-its-kind eye drop for diabetic macular edema, aiming at $10B+ markets.

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

At CES 2026, RobotEra's L7 humanoid and 'Hexa-Core' lineup showcase China's growing dominance in the global robotics race. Here's a deep dive.